Genmab jumps 32 pct on successful drug study

COPENHAGEN (Reuters) - Shares in Danish biotech firm Genmab (GEN.CO) rose 32 percent in early trade on Friday after an experimental treatment for leukemia it developed with GlaxoSmithKline (GSK.L) proved effective in a pivotal trial.

The companies said late on Thursday the antibody drug met its goal in the study of difficult-to-treat patients with chronic lymphocytic leukemia (LCC), producing a response rate well in excess of the 25 percent minimum needed.

By 3:07 a.m. EDT, Genmab traded up 31 percent at 336 crowns.

(Reporting by Gelu Sulugiuc; Editing by Paul Bolding)